Scinai Immunotherapeutics Ltd. has announced the successful closing of a $4 million financing through a private placement and warrant inducement. This significant funding will bolster the company's operations in its contract development and manufacturing organization (CDMO) and support its immunotherapy pipeline.
On October 16, 2026, Scinai issued a press release detailing the closing of the private placement, which included 2,458,334 American Depositary Shares (ADSs) and Series A-1 Warrants. Each ADS represents 40,000 ordinary shares. Additionally, the company executed the immediate exercise of existing warrants to purchase up to 879,194 ADSs at a reduced exercise price of $1.20 per ADS.
Background
Scinai Immunotherapeutics Ltd. operates within the biological products sector, specifically focusing on the development of immunotherapy solutions. The company trades on the Nasdaq under the ticker SCNI. Scinai is a non-accelerated filer and has been actively engaged in recent filings, including several 6-K forms, which detail its ongoing business activities.
What the Filing Says
The filing states, "Completing this financing, alongside our recently announced CDMO agreement, strengthens our ability to execute customer programs, develop our CDMO platform and selectively advance our immunotherapy pipeline," according to CEO Amir Reichman. The company plans to use the proceeds to advance customer programs and pursue additional CDMO contracts.
Impact
This financing may affect various stakeholders, including existing and potential customers, investors, and competitors in the biological products industry. With the additional capital, Scinai aims to enhance its service offerings and operational capabilities, potentially increasing its competitive edge.
What's Next
The filing does not say what happens next.